Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes

Table 3

Descriptive data and blood sample data for nondiabetic controls and patients with type 2 diabetes with or without statin treatment. Comparisons were made within groups, that is, nondiabetic controls with statin treatment versus nondiabetic controls without statin treatment and type 2 diabetes patients with statin treatment versus type 2 diabetes patients without statin treatment. HbA1c levels are given as NGSP (%) with IFCC values (mmol/mol) in parenthesis.

Variable	Nondiabetic; statins (n = 4)	Nondiabetic; no statins (n = 14)	Type 2 diabetes; statins (n = 14)	Type 2 diabetes; no statins (n = 13)
Age (years)	64.8 ± 2.7	65.6 ± 1.9	61.3 ± 2.1	62.6 ± 2.9
Weight (kg)	81.1 ± 9.7	90.9 ± 6.4	84.3 ± 4.8	95.4 ± 2.4
BMI (kg/m^2)	27.3 ± 1.8	29.5 ± 1.7	29.0 ± 1.7	31.4 ± 1.6
Waist (cm)	96.2 ± 7.8	103.7 ± 4.4	102.0 ± 4.6	107.0 ± 3.8
Hip (cm)	105.4 ± 4.7	109.1 ± 3.6	110.5 ± 4.7	112.3 ± 3.8
Waist-hip ratio	0.91 ± 0.05	0.87 ± 0.07	0.96 ± 0.03	0.98 ± 0.04
Fasting plasma cholesterol (mmol/L)	6.25 ± 0.79	6.16 ± 0.29	4.30 ± 0.27	4.85 ± 0.20
Fasting plasma HDL cholesterol (mmol/L)	1.35 ± 0.18	1.49 ± 0.11	1.16 ± 0.08	1.19 ± 0.06
Fasting plasma LDL cholesterol (mmol/L)	4.10 ± 0.68	3.95 ± 0.23	2.44 ± 0.23	3.16 ± 0.14*
Fasting plasma triacylglycerols (mmol/L)	1.82 ± 0.39	1.46 ± 0.17	1.52 ± 0.22	1.37 ± 0.10
Fasting plasma betatrophin (pg/mL)	542 ± 77	666 ± 82	858 ± 102	930 ± 130
HbA1c; (% (mmol/mol))	5.9 ± 0.2; (40.8 ± 2.1)	5.8 ± 0.1; (39.9 ± 0.8)	6.8 ± 0.2; (50.9 ± 2.5)	6.7 ± 0.2; (50.4 ± 2.1)
Fasting plasma glucose mmol/L	6.7 ± 0.4	6.0 ± 0.2	8.5 ± 0.6	8.5 ± 0.5

∗P < 0.05.